ReviewHuman

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders

Clinical pharmacokinetics, 2017 Aug. Minder EI, Barman-Aksoezen J, Schneider-Yin X.

Study type

Review

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Clinical pharmacokinetics

Published

2017 Aug

PubMed

PMID 28063031 ↗

DOI

10.1007/s40262-016-0501-5 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Afamelanotide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

Administration, CutaneousAdultClinical Trials as TopicDNA RepairDelayed-Action PreparationsDermatitis, PhototoxicDermatologic AgentsFemaleHumansMalePemphigus, Benign FamilialProtoporphyria, Erythropoietic

Other papers on Afamelanotide

Randomized controlled trial · 2015

Afamelanotide for Erythropoietic Protoporphyria

Review · 2019

Eruptive Melanocytic Nevi: A Review

Journal article · 2022

Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page